Transplant
From the Journals
Trial shows utility of small-volume blood collection tubes
A clinical trial in Canada has found that small-volume blood collection tubes equal standard-volume tubes for specimen capture while reducing...
Conference Coverage
DLBCL treatment options: CAR T outperforms ASCT
Relapsed and refractory DLBCL patients treated with CAR T-cell therapy achieved better outcomes than with autologous stem cell transplants.
Conference Coverage
Frontline myeloma treatments: ASCT vs. CAR T
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple...
Feature
Dispelling clinicians’ misconceptions about sickle cell disease
Among clinicians and their patients, widespread myths about sickle cell disease can stand in the way of adequate treatment.
News
FDA approves motixafortide for stem cell mobilization in myeloma
Motixafortide has been approved by the FDA to help mobilize hematopoietic stem cells in autologous transplants for patients with multiple myeloma...
Conference Coverage
Is additional treatment needed, pretransplant, for r/r AML?
The issue of whether or not patients with r/r AML require additional treatment pretransplant was debated at SOHO 2023.
From the Journals
Post-SCT, better survival in children with healthy gut diversity
After donor stem cell transplants, children with lower gut microbiota diversity show poorer survival and more complications.
From the Journals
Antibody shows promise in preventing GVHD
In translational research that shows potential for humans, an antibody blockade of the Notch signaling pathway prevents graft-versus-host-disease...
From the Journals
Neutropenia affects clinical presentation of pulmonary mucormycosis
Bronchoalveolar lavage was s stronger contributor to diagnosis in nonneutropenic patients.
Conference Coverage
Quizartinib boosts AML survival, regardless of SCT
The FLT-inhibitor drug shows survival benefits in patients with higher-risk FLT3 mutations, with or without prior stem cell transplant.
Conference Coverage
Phase 3 trial: Maribavir yields post-transplant benefits
Study findings “provide supportive evidence of the potential for long-term benefit” with maribavir for the treatment of post-transplant CMV.